Skip to content

Sunday, 22 November 2026 · New Delhi

Science & Tech· Prelims · GS-III

Rewriting Life: Biotechnology and Genetic Engineering

From reading DNA to rewriting it: genome sequencing, the Genome India Project, CRISPR, gene therapy and India's indigenous CAR-T breakthrough, with the BioE3 policy framing the bioeconomy push.

By Harsh28 September 2026Updated 22 November 202641 min readintermediate
Rewriting Life: Biotechnology and Genetic Engineering | UPSC

Biotechnology is the use of living organisms, or the biological systems and processes derived from them, to make products and solve human problems in health, farming, industry and the environment. Few fields touch the UPSC syllabus at as many points: one chapter can throw up prelims facts on vaccines and gene editing, and mains questions on bioethics, food security and the bioeconomy, the part of national output generated from biological resources and processes.

The living toolkit: what biotechnology is

At its simplest, biotechnology means putting biology to work. When yeast ferments sugar into alcohol, that is traditional biotechnology. When scientists reprogram a bacterium to manufacture human insulin, that is modern biotechnology, built on understanding and manipulating DNA, the molecule that carries the instructions for building and running a living cell. The field is often colour-coded by application, a classification UPSC frequently tests.

  • Red biotechnology covers medical and healthcare uses: drugs, vaccines, gene therapy and diagnostics.
  • Green biotechnology covers agriculture: genetically modified crops, biofertilisers and pest-resistant varieties.
  • White biotechnology covers industry: biofuels, bioplastics, enzymes and fermentation-based manufacturing.
  • Grey biotechnology covers the environment: bioremediation, or cleaning pollution with microbes, and waste treatment.
  • Blue biotechnology covers marine resources: aquaculture, marine drugs and algae-based products.
  • Yellow biotechnology covers food and nutrition: fermentation, fortified foods and probiotics.

The standard international definition, and the one the UPSC drew on in its 2018 and 2019 papers, comes from the United Nations Convention on Biological Diversity (UNCBD): 'Biotechnology encompasses any technological application that utilizes biological systems, living organisms, or their derivatives to create or modify products and processes for specific purposes.' The operative phrase is 'for specific purposes': a technique counts as biotechnology only when biology is deliberately harnessed to make or modify something useful.

India's bioeconomy has grown from about $10 billion in 2014 to over $165 billion in 2024, according to the India BioEconomy Report released by the Department of Biotechnology (DBT), with a stated ambition of $300 billion by 2030 and $1 trillion by 2047. India ranks among the world's largest biotech economies, holds the second-highest number of USFDA-approved manufacturing plants outside the US, and saw its biotech company count rise from 5,365 in 2021 to 10,075 in 2024. Just five states, Maharashtra, Karnataka, Telangana, Gujarat and Andhra Pradesh, generate more than two-thirds of this value, a concentration the government wants future biotech clusters to correct.

The India BioEconomy Report, published by the DBT, divides this bioeconomy into five segments:

Segment

What it covers

Bio-Pharma

Vaccines, biosimilars and biopharmaceuticals; India is the world's largest vaccine manufacturer

Bio-Services

Contract research, clinical trials and data services

Bio-Agriculture

Bt cotton, biopesticides, biofertilisers and biostimulants

Bio-Industrial

Enzymes, biofuels and bio-based chemicals

Bioinformatics

Genomic data analysis and computational biology

Reading the code of life: genome sequencing

A genome is the complete set of genetic instructions of an organism, all its DNA, including every gene. A gene is the basic unit of heredity, a stretch of DNA that carries the code for a protein or a regulatory function. Genome sequencing is the process of determining the exact order of the four DNA bases, adenine (A), cytosine (C), guanine (G) and thymine (T), along a strand of DNA. Think of it as reading the full instruction manual of life, letter by letter.

Sequencing typically runs through four steps. First, DNA shearing cuts long DNA into small fragments. Second, DNA barcoding tags each fragment so its origin can be tracked. Third, the sequencer reads the bases on every fragment. Fourth, bioinformatics, the use of computation to analyse biological data, reassembles the fragments and compares sequences to spot variations linked to disease, ancestry or traits.

The applications explain why governments fund it. In medicine, sequencing powers prenatal screening, rare-disease diagnosis and cancer genomics. In pharmacogenomics, the study of how genes affect drug response, it predicts who will benefit from a drug and who may suffer side effects. During the COVID-19 pandemic, rapid sequencing of the viral genome let scientists design vaccines and track new variants. In agriculture it speeds up breeding for disease resistance, and in forensics it identifies individuals from minute biological traces. The limits matter too: sequencing generates enormous data that needs advanced computing, it can miss large structural changes in DNA, much of the variation it finds has no known medical meaning yet, and the intimate nature of genetic data raises hard questions about privacy, insurance discrimination and consent.

Mapping a billion people: the Genome India Project

10,074Genomes sequencedComplete by Feb 2024180MGenetic variantsFrom 9,772 individuals44MNovel variantsNever seen in global databases20InstitutionsIITs, AIIMS, CSIR laboratories20,000Biobank samplesAt IISc Bengaluru4%MYBPC3 mutationCardiac risk factor in Indians
Mapping Indian genetic variation: the flagship project's numbers from launch to the 2025 Nature Genetics harvest.

The Genome India Project is a DBT-funded flagship programme, launched in January 2020, that set out to sequence the whole genomes of 10,000 Indians drawn from the country's diverse population groups. The logic is simple: global genetic databases are dominated by Western populations, so a drug dose, a disease-risk estimate or a diagnostic test calibrated abroad may simply not fit Indian bodies. India needed its own reference genome, a standard map of Indian genetic variation against which individual patients can be compared.

In February 2024 the Department of Biotechnology announced that whole genome sequencing of 10,074 individuals was complete. The data is archived at the Indian Biological Data Centre (IBDC) at Faridabad, India's first national life-science data repository, and a biobank of 20,000 blood samples has been established at the Centre for Brain Research at IISc Bengaluru for future research. Twenty institutions across the country, from IITs and AIIMS to CSIR laboratories, collaborated on the effort.

The first scientific harvest, published in Nature Genetics in April 2025, reported about 180 million genetic variants from 9,772 individuals, including roughly 44 million variants never seen in global databases. Early findings already matter for Indian medicine: the MYBPC3 mutation, a risk factor for cardiac conditions, was found in about 4 percent of Indians sampled, and population-specific patterns of anaesthesia response and cancer predisposition emerged from the data. A companion effort, IndiGen, undertaken by the Council of Scientific and Industrial Research (CSIR) from April 2019, sequences diverse ethnic groups to enable genetic epidemiology, the study of how genes shape disease patterns in populations.

Phase two of Genome India will compare the genomes of healthy people with those suffering from cancers, diabetes, neurological conditions and rare genetic diseases, hunting for the mutations that predispose Indians to illness. That comparison is the gateway to precision medicine, treatment tailored to a patient's genetic makeup rather than one-size-fits-all prescriptions, which is why the project is described as foundational infrastructure for Indian healthcare.

Rewriting the code: genetic engineering

Genetic engineering is the deliberate insertion, deletion or modification of genetic material in a cell to change an organism's characteristics. If sequencing is reading the manual of life, genetic engineering is editing it. Four toolkits dominate the field. Recombinant DNA technology moves a gene from one species into another, the classic example being bacteria engineered to produce human insulin. Gene editing tools such as CRISPR-Cas9, TALENs and ZFNs cut DNA at precise locations so faulty sequences can be repaired or removed. Gene silencing through RNA interference switches specific genes off without altering the DNA itself. And transgenesis creates organisms carrying foreign genes, such as pest-resistant crops.

CRISPR-Cas9 deserves its reputation as the defining tool of modern biology. Bacteria naturally use the CRISPR system as an immune memory: when a virus attacks, the bacterium stores a snippet of viral DNA and uses the Cas9 protein as molecular scissors to cut matching viral DNA on the next encounter. Scientists reprogrammed this defence into a programmable editor by attaching a guide RNA that leads Cas9 to any chosen DNA sequence. Because it is cheaper, faster and more precise than earlier methods, CRISPR is now in clinical trials for conditions like sickle cell anaemia, where a patient's own blood stem cells are edited to produce healthy haemoglobin.

Agriculture shows both the promise and the politics. Bt cotton, engineered with a bacterial gene that kills bollworm pests, covers the overwhelming majority of India's cotton area and is the country's most successful genetically modified crop. Golden Rice, fortified with beta-carotene that the body converts to vitamin A, targets hidden hunger. Indian researchers have developed Sahbhagi Dhan, a drought-tolerant rice variety, and ADVIKA, a drought-tolerant chickpea unveiled in late 2023. In medicine, engineered cells produce growth hormones and monoclonal antibodies, laboratory-made proteins that target specific disease molecules, while xenotransplantation research edits pig organs so they might one day be transplanted into humans.

Two frontiers beyond editing deserve their dictionary definitions. A gene drive is a genetic system engineered to spread a chosen set of genes rapidly through a wild population, biasing inheritance so that nearly all offspring carry the trait; researchers propose using it to suppress malaria-transmitting mosquitoes, which is also why ecologists fear an accidental release could be irreversible. Synthetic biology goes further: it redesigns existing biological organisms and even crafts entirely new forms of life, treating DNA as programmable code for manufacturing medicines, materials and fuels.

India is moving from CRISPR reader to CRISPR writer. At the National Agri-Food Biotechnology Institute (NABI) in Mohali, scientists used CRISPR-Cas9 to edit the banana genome, boosting beta-carotene up to sixfold for vitamin A enrichment, a first for a fruit crop in India. The Indian Agricultural Research Institute's Pusa Rice DST1 edits the DST gene for drought tolerance, with field tests underway. In medicine, the November 2025 unveiling of BIRSA-101 at CSIR-IGIB Delhi gave India its first indigenous CRISPR-based gene therapy for sickle cell disease, built on the home-grown enFnCas9 platform and licensed to the Serum Institute of India for affordable scale-up, in line with the national goal of a sickle-cell-free India by 2047.

India regulates this power through the Genetic Engineering Appraisal Committee (GEAC), the apex body under the Ministry of Environment, Forest and Climate Change that approves genetically modified organisms. The cautionary tale is Bt brinjal, placed under a moratorium in 2010 after public protests. Its counterpoint is Dhara Mustard Hybrid-11 (DMH-11), a GM mustard cleared by the GEAC in 2022 amid continuing legal scrutiny in the Supreme Court. In 2022 India also exempted SDN-1 and SDN-2 genome-edited plants, edits that introduce no foreign DNA, from the strictest biosafety regulations, signalling that regulation will distinguish between transgenic organisms and precise edits. The enduring concerns are gene flow to wild relatives, corporate control of seed markets, and whether long-term ecological effects are fully understood.

Three gene-editing tools work on the same cut-and-repair principle but differ in precision and cost:

Tool

How it works

Why it matters

CRISPR-Cas9

A guide RNA steers the Cas9 enzyme to a matching DNA sequence, where it cuts both strands: the famous "genetic scissors"

Modelled on the bacterial immune system; cheapest, fastest and most precise

Zinc finger nucleases (ZFNs)

Engineered proteins that grip specific DNA triplets, fused to a DNA-cutting enzyme

Precise but costly and hard to design

TALENs

Engineered proteins that read DNA one base at a time, fused to a cutting enzyme

More flexible than ZFNs, but bulkier to build

CRISPR-Cas9: find, cut, edittarget sequencePAMCas9 enzymeguide RNADouble-strand breakcell repair then deletes,corrects or inserts letters
CRISPR-Cas9 editing: a guide RNA matches a target DNA sequence beside a PAM marker, and the Cas9 enzyme cuts both strands there, letting the cell's repair machinery delete, fix or insert genetic letters.

Healing at the root: gene therapy

Gene therapy is a medical technique that treats or prevents disease by modifying a patient's genes: introducing a working copy of a faulty gene, silencing a harmful one, or repairing a mutation at its source. Unlike drugs that manage symptoms, gene therapy aims at the root cause, which makes it most powerful against monogenic disorders, diseases caused by a defect in a single gene.

India entered this frontier with its first-in-human gene therapy trial for haemophilia A, a bleeding disorder caused by missing or defective Factor VIII, a blood-clotting protein. Scientists at the Christian Medical College (CMC) Vellore, supported by the DBT and the Centre for Stem Cell Research (a unit of inStem Bengaluru), used a lentiviral vector, a modified virus, to insert a working Factor VIII gene into the patients' own blood-forming stem cells. The single-centre study enrolled five participants aged 22 to 41 and reported zero annualised bleeding rates with sustained Factor VIII production, results published online in the New England Journal of Medicine in December 2024. The stakes are large: India carries the world's second-largest haemophilia burden, an estimated 1.36 lakh people with haemophilia A, of whom only about 21,000 are registered, and lifelong clotting-factor infusions are expensive and burdensome.

A living drug: CAR-T cell therapy

CAR-T cell therapy, short for Chimeric Antigen Receptor T-cell therapy, is an advanced form of gene therapy that turns a patient's own immune cells into a cancer treatment, earning it the nickname of a living drug. T-cells are white blood cells that patrol the body for abnormal cells, but cancers often evade them. In CAR-T therapy, T-cells are extracted from the patient's blood through leukapheresis, genetically modified in a laboratory using a viral vector to carry a synthetic receptor (the CAR) that recognises a specific protein on cancer cells, multiplied into the billions, and infused back. The reprogrammed cells hunt down the cancer and keep multiplying inside the body, giving a long-lasting, self-sustaining attack.

Manufacturing a CAR-T dose takes three steps. First, T cells are collected from the patient's blood in a process called leukapheresis. Second, the cells are engineered in a laboratory: a gene for a chimeric antigen receptor, a synthetic protein that recognises a cancer marker such as CD19, is inserted using a viral vector. Third, the engineered cells are infused back into the patient's bloodstream, where they multiply and hunt cancer cells through the body. Because they are living cells that persist and divide inside the patient, CAR-T products are called 'living drugs', a phrase that also captures their risk: once infused, they cannot be switched off easily.

CAR-T: a living drug, step by step1. LeukapheresisT cells collectedfrom patient blood2. EngineeringCAR gene insertedinto the T cells3. Expansionengineered cellsgrown in the lab4. Infusioncells returned tohunt cancer cellsIndia's first: NexCAR19developed by ImmunoACT with Tata Memorial Hospital
CAR-T cell therapy in four steps: T cells are collected from the patient by leukapheresis, engineered with a chimeric antigen receptor, expanded in the lab and infused back as a living drug against cancer.

India's breakthrough is NexCAR19, the country's first indigenously developed CAR-T therapy, created by ImmunoACT, a company incubated at IIT Bombay, in collaboration with the Tata Memorial Hospital. In October 2023 the Central Drugs Standard Control Organisation (CDSCO) granted it market authorisation for relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukaemia in patients aged 15 and above, based on trials in 60 patients showing about a 70 percent overall response rate. The therapy targets the CD19 protein found on cancerous B-cells. President Droupadi Murmu formally launched it at IIT Bombay in April 2024, and its price of roughly Rs 30 to 40 lakh, about one-tenth of the Rs 3 to 4 crore charged abroad, makes it a landmark in affordable innovation. A second indigenous therapy, Qartemi from Immuneel Therapeutics, won CDSCO approval in January 2025.

The therapy is not without risks. Cytokine release syndrome (CRS), a violent immune overreaction causing fever, low blood pressure and breathing difficulty, can be life-threatening, and neurological toxicity can cause delirium or seizures. Because CD19 also sits on healthy B-cells, treatment wipes those out too, an on-target, off-tumor effect. Cancers can also relapse by shedding the target protein, a trick called antigen escape, and the therapy works far better in blood cancers than in solid tumours. Manufacturing is personalised and logistically demanding, which is why researchers are racing toward allogeneic CAR-T cells, off-the-shelf treatments made from donor cells, combination therapies, and next-generation designs.

3D bioprinting

If genetic engineering rewrites the code of life, 3D bioprinting tries to print the tissue that code builds. It is an additive manufacturing technique that constructs three-dimensional biological structures layer by layer, depositing bio-inks, printable mixtures of living cells suspended in supportive biomaterials such as hydrogels, water-swollen polymer networks that mimic the soft, wet environment cells inhabit inside the body, through a computer-controlled nozzle. The printer follows a digital blueprint, often derived from a patient's own medical scans, placing cell-laden droplets or filaments with micrometre precision so the construct echoes the architecture of real tissue.

Three families of printers dominate. Extrusion bioprinting, the workhorse, pushes bio-ink through a nozzle like toothpaste and handles the densest cell loads. Inkjet bioprinting fires tiny droplets, faster and gentler but limited to runnier inks. Laser-assisted bioprinting uses a laser pulse to transfer cells from a donor slide, achieving the finest resolution at the highest cost. In every case the printed construct must mature in a bioreactor, a vessel that supplies nutrients, oxygen and mechanical cues while cells multiply, fuse and begin behaving like tissue. The hardest engineering problem is vascularisation, growing the tiny blood vessels without which any tissue thicker than a few millimetres starves at its core.

The honest state of the art is scaffolds, models and patches, not transplantable organs. Printed skin and cartilage constructs are in advanced research and early clinical testing for wound healing and joint repair. Pharmaceutical companies use bioprinted liver and heart-tissue models for drug testing, because a speck of human-like tissue predicts toxicity far better than animal models or flat cell cultures, cutting both animal testing and late-stage drug failures. Research groups have printed simplified kidneys, hearts and ears, but these are anatomical models or immature tissues, not functional organs ready for transplant; vascularisation and the immune complexity of a whole organ remain unsolved.

Globally the field is led by university laboratories and startups in the United States and Europe, with growing research output from China; in India, institutes including IITs and AIIMS are reported to be working on bioprinted skin, cartilage and bone scaffolds, though the work remains largely at the research stage. The regulatory questions are live everywhere: is a printed tissue a medical device, a biologic drug, or something new, and which regulator approves it? Using a patient's own cells, autologous sourcing, sidesteps immune rejection and much of the stem-cell ethics debate, but donor-cell and embryonic stem-cell lines raise consent and sourcing questions. Add biosecurity, engineered tissues could in principle be misused, and the garage-biology concerns of the previous section apply here too. For the exam, bioprinting sits at the intersection of biotechnology, materials science and medical ethics, which is exactly why it keeps appearing in questions.

India's biotech engine: policy and institutions

Mar 2002Bt cotton approvedIndia's first commercial GM crop, kills bollworm2010Bt brinjal moratoriumRelease halted after public consultations2017National Biopharma Mission$250 million World Bank co-funded biopharma pushJan 2020Genome India ProjectDBT plan to sequence 10,000 Indian genomesFeb 202410,074 genomes doneSequencing complete; data archived at IBDC FaridabadAug 2024BioE3 PolicyBiotechnology for Economy, Environment and EmploymentDec 2024Gene therapy trialCMC Vellore's haemophilia A trial published in NEJM
From Bt cotton in 2002 to the BioE3 policy and the first gene therapy trial in 2024.

The institutional backbone is the Department of Biotechnology (DBT), which funds research and policy, and the Biotechnology Industry Research Assistance Council (BIRAC), which backs startups and industry partnerships. The National Biopharma Mission, launched in 2017 with World Bank co-funding of $250 million, supports affordable biopharmaceutical development, while the National Biotechnology Development Strategy (2021-25) set the recent policy direction. Flagship research homes include the National Institute of Immunology, the Centre for Cellular and Molecular Biology (CCMB), the National Centre for Biological Sciences (NCBS) and the IITs, and 94 incubators across 25 states now shepherd biotech startups.

The big policy bet is the BioE3 Policy, short for Biotechnology for Economy, Environment and Employment, approved by the Union Cabinet in August 2024. It aims to make India a global hub for high-performance biomanufacturing, producing medicines, materials and chemicals through biological rather than chemical processes, across the policy's six thematic sectors, backed by the Bio-RIDE scheme, with an outlay of Rs 9,197 crore, and by Bio-AI hubs that fuse artificial intelligence with biology. The vision is explicit: biotechnology as a growth pillar alongside information technology and energy, powering the road to a developed India by 2047.

Thematic sector

What it covers

High-value bio-based chemicals, biopolymers and enzymes

Bio-based chemicals, biodegradable plastics and specialty enzymes that replace petrochemical routes

Smart proteins and functional foods

Alternative proteins and nutrition products for health and food security

Precision biotherapeutics

Gene and cell therapies, targeted biologics and personalised treatments

Climate-resilient agriculture

Drought and heat tolerant crops and soil microbiome innovations

Carbon capture and its utilisation

Algae and microbial systems that convert captured CO2 into fuels and materials

Marine and space research

Biomanufacturing for food, health and materials in extreme environments

Tool

What it does

Example in use

Recombinant DNA technology

Moves a gene from one species into another

Human insulin produced in engineered bacteria

CRISPR-Cas9 gene editing

Cuts DNA at a precise spot for repair or removal

Clinical trials correcting sickle cell anaemia

RNA interference

Silences specific genes without changing DNA

Pest-resistant crops

Transgenesis

Inserts foreign genes to create new traits

Bt cotton resisting bollworm

Biosecurity in the garage age: DIY biology and its risks

A biohacker is a hobbyist or independent researcher who practises biology outside traditional laboratories, ordering DNA kits and gene-editing tools online the way an electronics hobbyist orders circuit boards. CRISPR-based kits that can cut and edit DNA are now sold commercially, and the convergence of AI models that can design genomic sequences with synthetic biology has pushed the entry barrier for pathogen engineering to a worrying low.

Biosecurity is the set of policies, practices and technologies that prevent biological research and materials from being misused. The concrete worry is engineered pathogens escaping a lab or being deliberately built, now that AI-designed sequences can be ordered as synthetic DNA. One proposed safeguard is digital watermarking of engineered organisms: inserting traceable DNA signatures into synthetic genomes so that any engineered microbe found in the wild can be traced back to its maker.

The same toolkit also serves forensics and cleanup. Lab-in-a-van DNA systems can identify disaster victims from samples within about ninety minutes; wildlife forensics uses DNA barcoding to trace ivory and pangolin scales back to poaching hotspots, curbing illegal trade; and engineered microbes are being put to work on pollution, from PETase enzymes that digest plastic to oil-zapper bacteria that clean spills and microbes designed to break down PFAS chemicals.

  • Screen DNA synthesis orders for dangerous sequences before they are shipped, the way banks screen for fraud.
  • Run the riskiest work in BSL-3 and BSL-4 containment labs, linked to One Health surveillance that watches for zoonotic spillovers from animals to humans.
  • Stress-test biosecurity systems deliberately in controlled settings, so that blind spots are found by defenders before they are found by misuse.
  • Extend international norms and export controls to cover AI-designed biological sequences, not just physical pathogens.

GM crops: India's contested harvest

A genetically modified (GM) crop is a plant whose genome has been altered by inserting one or more genes, usually with Agrobacterium or a gene gun, to give it a trait such as pest resistance. India has supplied some of prelims' most repeated questions from this theme, because the same few crops keep returning to the regulatory table.

How a transgenic plant is built

Three techniques insert foreign genes into plants. Recombinant DNA technology is the cut-and-paste core: restriction enzymes cut DNA at specific sites and a gene of interest, such as a bacterial insecticide gene, is pasted into a carrier molecule. A gene gun fires microscopic heavy-metal particles coated with the gene into plant cells with mechanical force, where the DNA integrates into the genome. Agrobacterium-mediated transformation exploits the soil bacterium Agrobacterium tumefaciens, which naturally transfers part of its own DNA into plant cells, to smuggle the gene of interest into the plant genome at essentially random positions.

Making a transgenic plant1. Cut the genedesired gene isolatedwith restriction enzymes2. Build the vectorgene spliced into aplasmid (recombinant DNA)3. Deliver itgene gun orAgrobacterium carries it in4. Transgenic plantplant cells grow into aplant with the new traitExample: Bt cottona bacterial gene gives insect resistance
Recombinant DNA technology: a desired gene is cut out, spliced into a plasmid vector, delivered into plant cells by a gene gun or Agrobacterium, and grown into a transgenic plant carrying the new trait.

The first commercial product of this toolkit was the Flavr Savr tomato, licensed for human consumption in the United States in 1994: an antisense gene suppressed the polygalacturonase enzyme that softens fruit, extending shelf life. Today GM soybean, maize and cotton dominate global biotech acreage, and people worldwide have consumed biotech crop products for over two decades.

Bollgard I cotton carries the cry1Ac gene from the soil bacterium Bacillus thuringiensis (Bt). Inside the plant the gene makes a protein toxin that kills bollworm larvae feeding on the crop, cutting pesticide use. It was the first Bt cotton cleared for India.

Bollgard II cotton carries two Bt genes, cry1Ac and cry2Ab, instead of one. The second toxin widens protection to more bollworm species and, crucially, slows the evolution of pest resistance, because an insect resistant to one toxin is still killed by the other. Prelims loves this pair: Bollgard I is cry1Ac alone, Bollgard II is cry1Ac plus cry2Ab.

DMH-11 is a genetically modified mustard developed at the University of Delhi using the barnase-barstar system. The barnase gene makes the plant male-sterile and the barstar gene restores fertility, a pairing that enables commercial hybrid seed production in a crop where hybridisation is otherwise difficult. Its clearance by the Genetic Engineering Appraisal Committee (GEAC) has been contested in courts and public debate.

Bt brinjal carries the cry1Ac gene for resistance to the fruit and shoot borer, and would have been India's first GM food crop. In 2010 the environment minister imposed a moratorium on its commercial release after public consultations across the country. Critics cited biosafety gaps, risks to brinjal's rich Indian biodiversity, and farmer dependence on seed companies; the moratorium still stands.

MON 863 is a Monsanto maize variety engineered for corn rootworm resistance. It became controversial when independent reanalysis of rat-feeding study data suggested possible liver and kidney effects, fuelling the allergenicity and toxicity debate around GM foods. Critics argued that regulatory safety assessments were too narrow; supporters pointed to approvals by multiple regulators. Prelims asks it as a name-recognition fact: MON 863 is a GM maize at the centre of a biosafety controversy.

Golden rice is rice engineered to produce beta-carotene, the orange pigment the body converts to vitamin A, in the grain endosperm. It was designed to fight vitamin A deficiency, a major cause of childhood blindness. Critics question how much vitamin A it can realistically deliver and argue for supplementation and dietary diversity instead. It remains the textbook example of a nutritionally enhanced GM crop.

Crop

Gene(s)

Status in India

Bt cotton (Bollgard I)

cry1Ac

Approved; the only GM crop grown commercially in India

Bt cotton (Bollgard II)

cry1Ac + cry2Ab

Approved; wider bollworm protection, slower resistance build-up

Bt brinjal

cry1Ac

Moratorium on commercial release since 2010

DMH-11 mustard

barnase-barstar

GEAC clearance contested in courts and public debate

Golden rice

beta-carotene pathway

Not in India; the classic nutrition biofortification example

The regulatory ladder runs from laboratory to field. The Review Committee on Genetic Manipulation (RCGM), functioning under the Department of Biotechnology, monitors research and development work involving GMOs. The Genetic Engineering Appraisal Committee (GEAC), a statutory body under the Ministry of Environment, Forest and Climate Change, approves environmental release under the 1989 Rules framed under the Environment (Protection) Act, 1986. State Biotechnology Coordination Committees (SBCCs) review safety practices at the state level, and District Level Committees (DLCs) oversee field-level compliance. On the food side, the Food Safety and Standards Act, 2006 bars the import, manufacture or sale of GM food without FSSAI approval. Bt cotton remains the only GM crop approved for commercial cultivation in India, and its herbicide-tolerant variant HTBt cotton, resistant to the herbicide glyphosate, has not received regulatory approval.

Cloning: copying life

Cloning is the scientific process of creating genetically identical copies of a living organism or cell. The landmark is Dolly the sheep, born in 1996 as the first mammal cloned from an adult cell, which proved that a specialised cell's nucleus still carries the full genetic programme needed to build a whole animal.

The workhorse method is somatic cell nuclear transfer (SCNT): the nucleus of a somatic, or body, cell is transferred into an egg cell whose own nucleus has been removed, the egg is stimulated to divide, and the resulting embryo is implanted into a surrogate mother. Gene cloning, a narrower technique, copies individual genes to produce proteins or modify existing ones.

Cloning by nuclear transfer (SCNT)1. Somatic cellnucleus taken from abody cell of the donor2. Enucleated eggegg cell with its ownnucleus removed3. Embryo formsfused cell divides intoan early embryo4. Surrogate and cloneembryo implanted; theoffspring is a cloneFirst success: Dolly the sheepthe first mammal cloned from an adult cell
Somatic cell nuclear transfer: the nucleus of a donor's body cell is placed into an egg stripped of its nucleus; the reconstructed cell grows into an embryo and, in a surrogate, into a genetic copy of the donor, as with Dolly the sheep.

The method keeps making headlines. In 2022 the Beijing-based company Sinogene Biotechnology announced Maya, the world's first cloned wild Arctic wolf, born to a beagle surrogate after 85 embryos were transferred into seven surrogates. In April 2025 the US company Colossal Biosciences announced three pups, Romulus, Remus and Khaleesi, marketed as revived dire wolves extinct for 10,000 years; independent experts and the IUCN Species Survival Commission's Canid Specialist Group noted that the animals are genetically engineered grey wolves carrying about 20 edited genes, not members of the extinct species, a controversy that shows how marketing can outrun taxonomy.

The ethical objections are familiar: clones could be exploited for commercial or military purposes; genetic defects in the donor repeat in the clone; and human reproductive cloning, widely condemned, raises questions of identity, consent and the commodification of life.

Better breeds: biotechnology for livestock

Genetic improvement of livestock means selecting and multiplying animals with superior traits using assisted reproduction. Artificial insemination (AI) places selected semen directly into the female reproductive tract; in-vitro fertilisation (IVF) fertilises eggs outside the body; and embryo transfer technology (ETT) implants the resulting embryos into surrogate mothers. Together they raise milk and meat yields, conserve indigenous breeds and build disease-free, climate-resilient herds without depending on exotic breeds.

The policy architecture is in place. The Rashtriya Gokul Mission, launched in 2014, conserves and upgrades indigenous cattle through AI programmes, IVF, MAITRI doorstep services and progeny-tested bull production. In August 2021 the National Institute of Animal Biotechnology (NIAB), Hyderabad released IndiGau, India's first cattle genomic chip: with 11,496 single-nucleotide-polymorphism markers, the world's largest cattle chip at launch, it identifies pure indigenous breeds such as Gir, Sahiwal, Kankrej and Ongole. The National Livestock Mission supports breed development, the e-Pashuhaat portal connects farmers with breeders for bovine germplasm, and the NDDB's INAPH system tracks breeding, nutrition and health data in real time.

The chip story has moved on since IndiGau. In 2025 a unified genomic chip was launched with two versions, the Gau Chip for cattle and the Mahish Chip for buffalo, developed by the Department of Animal Husbandry and Dairying so that farmers can identify high-quality animals early and make informed selection decisions, including identifying young high-quality bulls at an early age. The chips are tailored for Indian breeds. Alongside the chip, indigenous sex-sorted semen technology developed by the National Dairy Development Board produces over 90 percent female calves in artificial insemination, costs about Rs 250 a dose, and carries a target of at least 10 lakh sexed semen doses a year for the ongoing artificial insemination programme.

Biotechnology for energy independence by 2047

The UPSC 2025 mains paper asked how biotechnology can help India achieve energy independence by 2047, and the answer runs through biomass. Biotechnology converts farm residue into second-generation ethanol, cutting stubble burning while feeding the E20 ethanol-blending programme. Microbial processes turn organic waste into biogas and compressed bio-CNG under the GOBARdhan scheme and the SATAT initiative, which promotes bio-CNG as a transport fuel. Algae-based systems and engineered microbes capture carbon dioxide and convert it into fuels and materials, making biotechnology a bridge between the bioeconomy and a self-reliant, green energy system.

The biofuel cycleBiomass feedstockcrop residue, cane,algae, used oilConversionfermentation, digestion,transesterificationBiofuels in useethanol, biogas,bio-CNG for transportCarbon returnsCO2 released in use isabsorbed by new cropscarbonloop
The biofuel cycle is a loop: biomass feedstock is converted by fermentation or digestion into ethanol, biogas or bio-CNG, and the carbon released in use is the same carbon the next crop absorbs as it grows.

Cell and genetics: the prelims table

  • Mitosis: one cell divides into two identical cells, so the count doubles: 1, 2, 4, 8. Meiosis halves the chromosome number to form gametes.
  • Plant cell versus animal cell: a plant cell has a cell wall and plastids, stores food as starch and has its nucleus pushed to the side; an animal cell has no cell wall or plastids, stores food as glycogen and has a central nucleus. In division, a plant cell forms a cell plate, an animal cell forms a cleavage furrow.
  • Mendel's laws: the law of segregation and the law of independent assortment. A monohybrid cross gives a 3:1 ratio and a dihybrid cross gives 9:3:3:1. An allele is one form of a gene, and the dominant allele masks the recessive allele in a heterozygote. Worked example with tall and dwarf pea plants: tall (T) is dominant over dwarf (t), so TT and Tt plants are tall and only tt plants are dwarf, and a cross between two Tt parents gives tall and dwarf offspring in a 3:1 ratio.
  • Chromosomes and genes: a human cell has 46 chromosomes in 23 pairs. A gene is a segment of DNA that codes for a trait. DNA carries the code, RNA carries it out.
  • Mutation: a change in the DNA sequence. Most mutations are neutral or harmful; a few are useful and drive evolution.
  • Genetic disorders: Down syndrome is trisomy 21; sickle-cell anaemia and thalassaemia are disorders of haemoglobin; haemophilia and colour blindness are sex-linked.
  • Blood groups: group O is the universal donor and group AB is the universal recipient. The Rh factor decides whether blood is Rh positive or Rh negative.

Asked in SSC CGL 2026

Biofertilizers and plant biotechnology

  • Rhizobium: a bacterium that lives in the root nodules of legumes and fixes atmospheric nitrogen.
  • Azotobacter: a free-living bacterium that fixes nitrogen in the soil. Azospirillum does the same in association with cereal roots.
  • Mycorrhiza: a fungus that grows with plant roots and helps the plant absorb phosphorus and water.
  • Blue-green algae: used as a biofertilizer in paddy fields, where they fix nitrogen.
  • Tissue culture: growing whole plants from a small piece of tissue in a sterile nutrient medium. It produces large numbers of identical, disease-free plants, a process called micropropagation.

Asked in SSC CGL 2026

Frequently asked questions

What is the difference between gene therapy and gene editing?

Gene editing is a tool, it changes DNA sequences, as CRISPR-Cas9 does. Gene therapy is a treatment strategy that may use gene editing, or gene addition via vectors, to cure disease. All therapeutic gene editing is gene therapy, but not all gene therapy involves editing: the haemophilia A trial added a working gene without editing the faulty one.

Why does India need its own genome database?

Because genetic variation differs across populations, and global databases are dominated by European ancestry. Without an Indian reference, disease-risk estimates, drug doses and diagnostic tests calibrated abroad can mislead Indian doctors. Genome India fills that gap with 10,000 sequenced Indian genomes.

What is the BioE3 Policy?

BioE3 stands for Biotechnology for Economy, Environment and Employment. Approved in August 2024, it aims to make India a global hub for high-performance biomanufacturing across the policy's six thematic sectors: high-value bio-based chemicals, biopolymers and enzymes; smart proteins and functional foods; precision biotherapeutics; climate-resilient agriculture; carbon capture and its utilisation; and marine and space research.

Is CAR-T therapy a cure for cancer?

Not yet. It produces durable remissions in many blood-cancer patients who had exhausted other options, with about a 70 percent response rate in NexCAR19 trials, but relapses occur through antigen escape, it works poorly in solid tumours so far, and side effects like cytokine release syndrome need expert management. It is best seen as a transformative platform, not a universal cure.

Stem cell and gene therapies move under central licensing

In July 2026 the Drugs Rules, 1945 were amended to bring three more product families under the Centrally Licensed Approving Authority (CLAA) framework: cell and stem cell derived products, gene therapy products, and xenografts. Until then, central licensing covered only a short list of specified products; the amendment extends the same single-window scrutiny to the newest generation of biological medicines.

How the CLAA framework works

  • Regulator: the Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare.
  • Flow: the State Licensing Authority examines the application and manufacturing compliance first, then forwards its recommendation to the CLAA, which evaluates it independently and takes the licensing decision.
  • Purpose: consistent licensing standards across states, tighter quality control, and stronger safety oversight of critical drugs and biological products.
  • Earlier coverage: specified products such as vaccines, large-volume parenterals (intravenous fluids above 100 ml), and recombinant DNA based medicines.
  • New coverage: stem cell derived products, gene therapy products, and xenografts (animal-derived graft material).
CLAA licensing flow1. State Licensing Authorityexamines application andmanufacturing compliance2. CLAA evaluationindependent evaluation ofthe recommendation3. Licensing decisionCLAA decides on thelicence for the productNew coverage from July 2026: stem cell products, gene therapy products, xenografts
Central licensing of stem cell and gene therapy products: the State Licensing Authority examines the application and manufacturing compliance, then forwards its recommendation to the Centrally Licensed Approving Authority, which evaluates it independently and takes the licensing decision. Regulator: CDSCO, under the Ministry of Health and Family Welfare.

The change matters for prelims because it sits at the junction of two high-yield topics: the regulation of biologicals, and the therapies themselves. Stem cell therapy is regenerative medicine built on cells that can renew themselves and mature into specialised types; gene therapy treats disease by introducing, replacing, modifying or regulating genetic material inside a patient's cells. Both are covered in depth in the gene therapy and CAR-T sections of this article, and both now pass through the same central licensing gate as vaccines.

Raygun: AI that resizes proteins without breaking them

Scientists at Duke University have built Raygun, an artificial intelligence system that can shrink, enlarge and rewrite proteins while preserving their function. Proteins are chains of twenty amino acids whose sequence decides how they fold and what they do, so changing a protein's length usually risks breaking it. Raygun treats length as a design variable rather than a fixed property.

  • Method: protein language models trained on millions of protein sequences, learning the links between sequence, structure and function.
  • Single-step generation: Raygun can produce a protein of a chosen target length in one step, instead of the repeated refinement that earlier design tools needed.
  • What it changes: the length and the amino-acid sequence of a protein, while keeping the function the protein performs.
Raygun: resize a protein, keep its functionInput proteinamino-acid sequence,fixed natural lengthProtein language modeltrained on millions ofprotein sequencesOutput proteinchosen target length,same function, one stepWhy it matterssmaller gene-therapy parts, compact therapeutic proteins, synthetic biology
Raygun (Duke University): protein language models trained on millions of sequences learn how sequence, structure and function relate, then generate a protein of a chosen target length in a single step, shrinking, enlarging or rewriting it while preserving its function.

Why it matters

  • Gene therapy: smaller protein components could fit inside viral delivery systems whose cargo capacity is limited.
  • Drug development: compact, purpose-built therapeutic proteins become easier to design.
  • Synthetic biology: new biological components and molecular tools can be built to a chosen size.
  • Basic research: smaller fluorescent or reporter proteins interfere less with the protein being studied.

For the exam, the core idea is one line: an AI model that reads protein sequences the way a language model reads text, and writes new proteins of a specified length that still work.

Key Terms

  • Biotechnology: Biotechnology is the use of living organisms, cells or biological processes to develop products and technologies for medicine, agriculture, industry and the environment. It ranges from traditional fermentation to modern genetic engineering, gene editing and biopharmaceutical production. Example: Bt cotton, a genetically engineered insect-resistant variety widely grown in India, is a leading agricultural product of biotechnology.
  • Bioeconomy: The bioeconomy is the part of the economy based on biological resources and processes: agriculture, forestry, fisheries, food, biofuels, bioplastics, biotechnology products and bio-based services. It offers a pathway to decouple growth from fossil resources by valorising renewable biomass and waste streams into fuels, materials and medicines. India has set a target of a 300 billion dollar bioeconomy by 2030, backed by the BioE3 policy promoting high-performance biomanufacturing. Example: Ethanol blending in petrol and enzyme-based bioplastics are everyday outputs of the bioeconomy.
  • Genome India Project: The Genome India Project is a Department of Biotechnology initiative launched in 2020 to sequence 10,000 genomes representing India's diverse populations. It aims to build a reference database of Indian genetic variation to support precision medicine, disease prediction and targeted drug development. Example: The project sequences 10,000 genomes from diverse Indian populations to map genetic variants linked to diseases common in India.
  • Genetic engineering: Genetic engineering is the direct manipulation of an organism's genes using recombinant DNA technology, most often by inserting a foreign gene to create a transgenic organism with a desired trait. It differs from conventional breeding by crossing species barriers in a single step rather than over many generations of selection. Example: Bt cotton, engineered with genes from the bacterium Bacillus thuringiensis, produces its own insecticidal protein against bollworms and is India's only commercially approved GM crop.
  • Gene editing: Gene editing is the precise modification of an organism's DNA at targeted locations using molecular tools such as CRISPR-Cas9, TALENs and zinc-finger nucleases. Unlike older genetic engineering, which inserts foreign DNA more randomly, gene editing can add, remove or replace specific DNA sequences with high precision, and it is used in medicine, crop improvement and research. Example: Casgevy, the first CRISPR-based therapy approved in 2023, treats sickle cell disease and transfusion-dependent beta thalassaemia by editing the patient's own blood stem cells.
  • CRISPR-Cas9: CRISPR-Cas9 is a gene-editing tool adapted from a natural defence system that bacteria use against viruses. A guide RNA directs the Cas9 enzyme to a precise location in DNA, where the enzyme cuts the strand, allowing scientists to delete, repair or insert genes with high accuracy. It is far cheaper, faster and more precise than earlier editing methods, which is why it won the 2020 Nobel Prize in Chemistry for Jennifer Doudna and Emmanuelle Charpentier. Example: Indian scientists are using CRISPR to develop pest-resistant and biofortified crops, and CRISPR-based therapies for sickle cell disease have entered clinical use globally.
  • Bt cotton: Cotton genetically engineered with genes from the soil bacterium Bacillus thuringiensis (Bt), producing proteins toxic to bollworm pests. Approved for commercial cultivation in India in March 2002, it now covers the overwhelming majority of India's cotton area and sharply cut bollworm pesticide use in its early years. Its later vulnerability to pink bollworm is a standard case study on pest resistance to a single toxin. Example: Bt cotton's cry proteins kill American bollworm larvae, which reduced insecticide sprays when it was first adopted.
  • Golden Rice: Golden Rice is a genetically engineered variety of rice enriched with beta-carotene, a precursor of vitamin A, giving the grains their characteristic golden colour. Developed as a humanitarian project by scientists Ingo Potrykus and Peter Beyer to combat vitamin A deficiency, which causes blindness and mortality among children in developing countries, it remains one of the most debated GM crops. Example: The Philippines approved Golden Rice for commercial cultivation in 2021, becoming the first country to do so.
  • Bt brinjal: A genetically modified brinjal (eggplant) developed with a Bt gene to resist the fruit-and-shoot borer pest. India's Genetic Engineering Appraisal Committee recommended it for commercial release in October 2009, but Environment Minister Jairam Ramesh imposed an indefinite moratorium in February 2010 after public consultations and protests. It remains India's cautionary precedent on GM food crops, while Bangladesh commercialised Bt brinjal in 2013. Example: The 2010 moratorium on Bt brinjal is the standard UPSC example of the precautionary principle in GM regulation.
  • SDN-1 and SDN-2: SDN-1 and SDN-2 are the first two categories of site-directed nuclease (SDN) genome-editing outcomes in plants. In SDN-1, a targeted nuclease such as CRISPR-Cas9 creates a DNA break that the cell repairs on its own, producing small insertions or deletions; in SDN-2, a short repair template guides the cell to make precise small changes. Neither introduces foreign DNA, so the edited plants are treated differently from transgenic GMOs. In 2022 India exempted SDN-1 and SDN-2 genome-edited plants from the strictest biosafety regulations that apply to GM crops. Example: The 2022 exemption of SDN-1 and SDN-2 edits from full GM-crop regulation in India.
  • NexCAR19: India's first indigenously developed CAR-T cell therapy, a personalised cancer treatment in which a patient's own T cells are genetically engineered to express a chimeric antigen receptor targeting the CD19 protein on cancerous B cells. Developed by ImmunoACT, an IIT Bombay-incubated company, with Tata Memorial Centre, it received CDSCO market authorisation in October 2023 for relapsed or refractory B-cell lymphomas and leukaemia, at roughly one-tenth the cost of imported CAR-T therapies. Example: Priced at about Rs 30 lakh to Rs 40 lakh per patient against Rs 3 crore to Rs 4 crore abroad, it showed a 70 per cent overall response rate in its 60-patient pivotal trial.
  • BioE3 Policy: The BioE3 Policy, short for Biotechnology for Economy, Environment and Employment, was approved by the Union Cabinet in August 2024 to foster high-performance biomanufacturing in India. It provides innovation-driven support for research, development and entrepreneurship across six thematic areas, including bio-based chemicals, precision biotherapeutics, climate-resilient agriculture and carbon capture. The policy aims to grow India's bioeconomy from over 130 billion US dollars in 2024 toward 300 billion dollars by 2030, supporting net-zero and green growth goals. Example: Under BioE3, the government is establishing biomanufacturing facilities, bio-AI hubs and biofoundries to take biotech innovations from lab to market.
  • Department of Biotechnology (DBT): The Department of Biotechnology (DBT) is the department under India's Ministry of Science and Technology responsible for promoting biotechnology research, industry and translation. It funds research institutions, biotech parks and startups, and runs missions on biopharma, biofuels and genomics, while biosafety approvals for genetically modified organisms go through the Genetic Engineering Appraisal Committee (GEAC) under the Environment Ministry. DBT is the government's main vehicle for turning India's life-sciences research into industrial and public-health outcomes. Example: DBT anchored the National Biopharma Mission, which backed indigenous vaccine and biotherapeutic development.
  • Genetic Engineering Appraisal Committee (GEAC): The Genetic Engineering Appraisal Committee (GEAC) is the apex statutory body under the Environment (Protection) Act, 1986, functioning under the Ministry of Environment, Forest and Climate Change. It appraises and approves activities involving genetically modified organisms, including field trials, environmental release and import or export of GM material. It was earlier called the Genetic Engineering Approval Committee and was renamed in 2010. Example: GEAC cleared Bt brinjal for environmental release in 2009, after which the government placed it under a moratorium in 2010.
  • Dhara Mustard Hybrid-11 (DMH-11): Dhara Mustard Hybrid-11 (DMH-11) is India's first transgenic mustard hybrid, developed at the Centre for Genetic Manipulation of Crop Plants (CGMCP), University of Delhi, by the team of Deepak Pental. It is a cross between the Indian variety Varuna and the East European Early Heera-2, using the barnase-barstar gene system (genes from the soil bacterium Bacillus amyloliquefaciens) to create male sterility in one parent and restore fertility in the hybrid. In October 2022 the Genetic Engineering Appraisal Committee (GEAC) approved its environmental release, making it the first genetically modified food crop cleared in India (Bt cotton, the only earlier clearance, is a non-food crop). Example: ICAR-supervised field trials reported DMH-11 yielding about 28 percent more than its parent variety Varuna.

Prelims practice

0 of 5 answered · 0 correct

Q1Prelims practice

With reference to the Genome India Project, consider the following statements:

1. It is funded and coordinated by the Department of Biotechnology.

2. It aims to sequence the whole genomes of 10,000 individuals representing India's diverse population.

3. The sequenced data is archived at the Indian Biological Data Centre, Faridabad.

Q2Prelims practice

The CRISPR-Cas9 system used in gene editing is derived from:

Q3Prelims practice

With reference to NexCAR19, consider the following statements:

1. It is India's first indigenously developed CAR-T cell therapy.

2. It targets the CD19 protein on cancerous B-cells.

3. It is primarily used for treating solid tumours.

Q4Prelims practice

The BioE3 Policy, approved in 2024, stands for:

Q5Prelims practice

With reference to India's first human gene therapy trial for haemophilia A, consider the following statements:

1. It was conducted at the Christian Medical College, Vellore.

2. It used a lentiviral vector to insert a working Factor VIII gene into patients' own blood-forming stem cells.

3. All five enrolled participants reported zero annualised bleeding rates.

Mains Practice question

150 words: The Genome India Project is a prerequisite for precision medicine in India. Discuss.

  • Define and locate: DBT-funded project (January 2020), 10,000 Indian whole genomes sequenced by 2024, data at IBDC Faridabad, findings in Nature Genetics (April 2025).
  • Why prerequisite: Western reference databases under-represent Indian diversity; precision medicine needs population-specific variant catalogues (example: MYBPC3 in 4 percent of Indians).
  • Applications: pharmacogenomics, disease-risk prediction, affordable genome-wide arrays for diagnostics, Phase II disease comparisons.
  • Caveats: data privacy and consent, equitable access to precision therapies, need for clinician and counsellor capacity.

250 words: Gene editing technologies such as CRISPR-Cas9 raise profound ethical and regulatory questions. Examine with reference to India's framework.

  • The technology: programmable editing via guide RNA and Cas9; somatic vs germline edits; therapeutic vs enhancement uses.
  • Ethical concerns: heritable changes, designer babies, equity of access, ecological release of edited organisms, consent.
  • India's framework: GEAC as apex regulator; Bt brinjal moratorium (2010) as cautionary precedent; DMH-11 clearance (2022) with judicial scrutiny; 2022 exemption for SDN-1/SDN-2 edits without foreign DNA.
  • Way forward: risk-proportionate regulation, transparent public consultation, ethics review for clinical applications, global harmonisation.

150 words: Discuss the significance of the indigenous CAR-T therapy NexCAR19 for cancer care in India.

  • The milestone: first indigenous CAR-T, CDSCO approval October 2023, IIT Bombay plus Tata Memorial plus ImmunoACT, launched April 2024.
  • Significance: cost of Rs 30-40 lakh vs Rs 3-4 crore abroad (frugal innovation), Atmanirbhar Bharat in advanced therapy, living-drug platform for future cell therapies.
  • Limits: blood cancers only so far, CRS and neurotoxicity risks, antigen escape, personalised manufacturing bottlenecks; Qartemi (2025) shows ecosystem deepening.
Science TechBiotechnologyupsc-prelimsGS Paper 3explained

Asked in the mains

Previous-year questions from this topic

How UPSC has actually asked this topic — with the year and marks for each question.

  1. 201815 marks

    Why is there so much activity in the field of biotechnology in our country? How has this activity benefitted the field of biopharma?

  2. 201915 marks

    How can biotechnology improve the living standards of farmers?

  3. 202115 marks

    What are the research and developmental achievements in applied biotechnology? How will these achievements help to uplift the poor sections of the society?

  4. 202210 marks

    Each year a large amount of plant material, cellulose, is deposited on the surface of Planet Earth. What are the natural processes this cellulose undergoes before yielding carbon dioxide, water and other end products?

Asked in the prelims

Previous-year MCQs from this topic

How UPSC has tested this topic in the prelims — pick an option to test yourself.

  1. 2026Prelims

    1.Which of the following statements with regard to genetic medicine is/are correct? 1. Genetic medicines correct/compensate for the faulty genes responsible for disease. 2. Engineered viruses and lipid nanoparticles are used as carriers of the genetic medicine. 3. Genetic medicines alter the entire DNA sequence.

  2. 2026Prelims

    2.Which of the following statements with regard to Genome India Project is/are correct? 1. It is a part of the Human Genome Project. 2. The project is funded by the Department of Biotechnology (DBT), Government of India. 3. Its primary aim is to build a catalogue of genetic diversity of the Indian population.

  3. 2020Prelims

    3.Consider the following statements: (1) Genetic changes can be introduced in the cells that produce eggs or sperms of a prospective parent. (2) A person’s genome can be edited before birth at the early embryonic stage. (3) Human induced pluripotent stem cells can be injected into the embryo of a pig. Which of the statements given above is/ are correct?

  4. 2019Prelims

    4.What is Cas9 protein that is often mentioned in news?

  5. 2019Prelims

    5.With reference to the recent developments in science, which one of the following statements is not correct?

  6. 2019Prelims

    6.RNA interference (RNAi)’ technology has gained popularity in the last few years. Why? 1. It is used in developing gene silencing therapies. 2. It can be used in developing therapies for-the treatment of cancer. 3. It can be used to develop hormone replacement therapies. 4. It can be used to produce crop plants that are resistant to viral pathogens. Select the correct answer using the code given below.

  7. 2017Prelims

    7.With reference to agriculture in India, how can the technique of `genome sequencing’, often seen in the news, be used in the immediate future? 1. Genome sequencing can be used to identify genetic markers far disease resistance and drought tolerance in various crop plants. 2. This technique helps in reducing the time required to develop new varieties of crop plants. 3. It can be used to decipher the host-pathogen relationships in crops. Select the correct- answer using the code given below:

  8. 2013Prelims

    8.Recombinant DNA technology (Genetic Engineering) allows genes to be transferred (1). across different species of plants (2). from animals to plants (3). from microorganisms to higher organisms Select the correct answer using the codes given below.

  9. 2011Prelims

    9.At present, scientists can determine the arrangement or relative positions of genes or DNA sequences on a chromosome. How does this knowledge benefit us? 1. It is possible to know the pedigree of livestock. 2. It is possible to understand the causes of all human diseases. 3. It is possible to develop disease-resistant animal breeds.

  10. 2014Prelims

    10.Consider the following techniques/ phenomena: 1. Budding and grafting in fruit plants 2. Cytoplasmic male sterility 3. Gene silencing Which of the above is/are used to create transgenic crops?

  11. 2018Prelims

    11.Consider the following pairs : Terms sometimes seen in news Context /Topic Belle II experiment Artificial Intelligence Blockchain technology Digital/ Cryptocurrency CRISPR — Cas9 Particle Physics Which of the pairs given above is/are correctly matched?

  12. 2021Prelims

    12.“Bollgard I and Bollgard II technologies are mentioned in the context of:

  13. 2018Prelims

    13.With reference to the Genetically Modified mustard (GM mustard) developed in India, consider the following statements : 1.GM mustard has the genes of a soil bacterium that give the plant the property of pest-resistance to a wide variety of pests. 2.GM mustard has the genes that allow the plant cross-pollination and hybridization. 3.GM mustard has been developed jointly by the IARI and Punjab Agricultural University. Which of the statements given above is/are correct ?

  14. 2012Prelims

    14.Other than resistance to pests, what are the prospects for which genetically engineered plants have been created? 1. To enable them to withstand drought 2. To increase the nutritive value of the produce 3. To enable them to grow and do photosynthesis in spaceships and space stations 4. To increase their shelf life.

  15. 2012Prelims

    15.What are the reasons for the people’s resistance to the introduction of BT brinjal in India? 1. Bt brinjal has been created by inserting a gene from a soil fungus into its genome. 2. The seeds of Bt brinjal are terminator seeds and therefore, the farmers have to buy the seeds before every season from the seed companies. 3. There is an apprehension that the consumption of Bt brinjal may have adverse impact on health. 4. There is some concern that the introduction of BT brinjal may have adverse effect on the biodiversity. Select the correct answer using the code given below:

  16. 2011Prelims

    16.A genetically engineered form of brinjal, known as the Bt-Brinjal, has been developed. The objective of this is

  17. 2010Prelims

    17.Mon 863 is a variety of maize. It was in the news for the following reason

  18. 2010Prelims

    18.Genetically modified “golden rice” has been engineered to meet human nutritional requirements. Which one of the following statements best qualifies golden rice?

Related articles

Continue your preparation with more on this topic.

Nuclear power in space: RTGs, reactors, propulsion and the law | UPSCScience & TechNuclear power in space: RTGs, reactors, propulsion and the lawBeyond Mars, sunlight is too weak for solar panels and a lunar night lasts two weeks. Nuclear power, from radioisotope generators to fission reactors and nuclear propulsion, is how deep-space missions and Moon bases will keep running, and the rules that must keep it safe.Defence technology for prelims: missiles, submarines, aircraft and DRDO | UPSCScience & TechDefence technology for prelims: missiles, submarines, aircraft and DRDOMissiles, submarines, fighter aircraft and the organisation that builds them: the defence technology facts prelims repeats, from Agni-V and BrahMos to Tejas, INS Arihant and INS Vagir, with tables and practice questions.Human biology facts for prelims: physiology, vitamins, diseases and cells | UPSCScience & TechHuman biology facts for prelims: physiology, vitamins, diseases and cellsPhysiology, vitamins and ICMR-NIN 2020 mineral intakes, diseases, cells and nutrition: the human biology facts prelims repeats, with tables, practice questions and model answers.Chemistry facts for prelims: periodic table, everyday chemicals, fuels and alloys | UPSCScience & TechChemistry facts for prelims: periodic table, everyday chemicals, fuels and alloysPeriodic table extremes, everyday chemicals with their common names, fuels, alloys, ores and polymers: the chemistry facts prelims tests, with tables, practice questions and model answers.General physics facts for prelims: SI units, mechanics, electricity, sound and light | UPSCScience & TechGeneral physics facts for prelims: SI units, mechanics, electricity, sound and lightSI units, scalar and vector quantities, mechanics worked values, electricity and magnetism, sound, light and heat: the general physics facts prelims repeats, with tables, practice questions and model answers.Nobel Prizes 2026: six laureates, six frontiers | UPSCScience & TechNobel Prizes 2026: six laureates, six frontiersOptogenetics, neutrino astronomy, asymmetric synthesis, Anne Carson, Navi Pillay and the microeconomics of stabilisation — all six 2026 Nobel Prizes in one note, with the laureates and citations to bank for prelims.